Brown Brothers Harriman & Co. Has $50,000 Position in Genelux Co. (NASDAQ:GNLX)

Brown Brothers Harriman & Co. raised its position in Genelux Co. (NASDAQ:GNLX) by 76.2% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 21,075 shares of the company’s stock after purchasing an additional 9,114 shares during the quarter. Brown Brothers Harriman & Co.’s holdings in Genelux were worth $50,000 as of its most recent SEC filing.

A number of other hedge funds have also recently made changes to their positions in GNLX. LifeSteps Financial Inc. raised its holdings in Genelux by 17.6% in the 3rd quarter. LifeSteps Financial Inc. now owns 78,255 shares of the company’s stock valued at $185,000 after buying an additional 11,719 shares during the last quarter. Exchange Traded Concepts LLC increased its position in Genelux by 89.0% in the 3rd quarter. Exchange Traded Concepts LLC now owns 65,930 shares of the company’s stock valued at $156,000 after acquiring an additional 31,047 shares during the period. Miracle Mile Advisors LLC raised its stake in shares of Genelux by 33.3% during the third quarter. Miracle Mile Advisors LLC now owns 40,000 shares of the company’s stock valued at $95,000 after acquiring an additional 10,000 shares during the last quarter. Cubist Systematic Strategies LLC acquired a new position in shares of Genelux during the second quarter worth $56,000. Finally, Point72 Asia Singapore Pte. Ltd. bought a new stake in shares of Genelux in the second quarter worth $39,000. 37.33% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Genelux

In related news, major shareholder Aladar Szalay sold 42,818 shares of the business’s stock in a transaction on Tuesday, September 3rd. The shares were sold at an average price of $2.09, for a total transaction of $89,489.62. Following the transaction, the insider now owns 739,821 shares in the company, valued at $1,546,225.89. The trade was a 5.47 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Over the last three months, insiders have sold 132,387 shares of company stock valued at $324,342. 9.30% of the stock is currently owned by company insiders.

Genelux Price Performance

Shares of Genelux stock opened at $2.69 on Friday. The stock’s 50-day moving average is $2.65 and its 200 day moving average is $2.52. Genelux Co. has a one year low of $1.60 and a one year high of $16.60. The firm has a market cap of $92.91 million, a price-to-earnings ratio of -2.83 and a beta of -1.85.

Analyst Upgrades and Downgrades

GNLX has been the subject of several analyst reports. HC Wainwright lowered their target price on Genelux from $32.00 to $30.00 and set a “buy” rating for the company in a research report on Friday, November 15th. Roth Mkm initiated coverage on Genelux in a research note on Tuesday, August 27th. They issued a “buy” rating and a $10.00 price objective on the stock. Guggenheim assumed coverage on Genelux in a report on Tuesday, October 29th. They issued a “buy” rating and a $8.00 target price on the stock. Finally, Roth Capital upgraded shares of Genelux to a “strong-buy” rating in a report on Tuesday, August 27th. Four research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Buy” and a consensus price target of $18.25.

Genelux Company Profile

Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small cell lung cancer.